THE BIOLOGY AND TREATMENT OF HUMAN LEUKEMIA AND LYMPHOMA

在这项提议中，我们再次强调了人类的生物学 白血病和淋巴瘤细胞，并详细介绍了 都是在该项目第二年的过程中进行的。这个 整合涉及表征的基础研究 造血干细胞和造血细胞通过免疫学、细胞学、 细胞培养技术已经对我们的临床产生了影响 治疗方案。在未来的一年里，我们将致力于 用于表征早期T细胞的细胞表面和分子探针 利用我们对T细胞受体基因的了解来治疗细胞恶性肿瘤 重新安排。此外，我们会继续进行针对 正常骨髓干细胞的鉴定及其在白血病中的克隆形成 利用免疫学、细胞遗传学和分子探针的对应物。 单抗已经被证明是非常重要的 将获得诊断和越来越多的证据来支持这一概念 在预后上重要的组可以定义为B细胞和 髓系白血病。J2和J2的自体骨髓移植计划 J5将继续，因为到目前为止的数据表明，这一方法 与在同种异体配对系统中获得的结果相比是有利的。 对B1方案的研究表明，它是一种主要的新疗法 先前无反应的非霍奇金淋巴瘤的治疗模式。抗B-Lym 将利用多肽抗体进行分离和鉴定 希望这些新的试剂将会 补充现有抗体，以确定白血病的特征。戴维斯博士。 Kufe，Faller和Frei已经展示了新的药理学方法 可优化治疗AML、ALL等肿瘤。这些 调查将继续利用联合化疗治疗 自体移植中残留肿瘤的细胞照射--天冬酰胺酶 治疗ALL和小剂量Ara-C萨兰博士取得的进展， Weinstein和Mayer在ALL和AML化疗中的应用 免疫疗法给人们带来了希望，即这些疾病中的大多数 最终都是可以治愈的。目前方案已导致多项 对免疫学、分子生物学感兴趣的个体之间的相互作用 生物学、细胞表面抗原、药理学、血液学和肿瘤学。我们 相信这种癌症治疗和诊断的综合方法具有 已经使人们更好地了解了恶性细胞及其 控制力。

In this proposal we have once again emphasized the biology of human leukemia and lymphoma cells and have detailed the accomplishments which have taken place during the course of the second year of this project. The integration of basic studies involving the characterization of hematopoietic stem cells and hematopoietic cells by immunologic, cytologic, and cell culture techniques has already had an impact on our clinical treatment programs. In the next year, we will pursue the development of cell surface and molecular probes for the characterization of the early T cell malignancies utilizing our understanding of T cell receptor gene rearrangements. In addition, we will pursue studies directed at the identification of normal myeloid stem cells and their leukemic clonogenic counterparts utilizing immunologic, cytogenetic and molecular probes. Monoclonal antibodies have proved to be extraordinarily important for diagnosis and increasing evidence will be obtained to support the notion that prognostically important groups can be defined for both B cell and myeloid leukemias. Autologous bone marrow transplant program with J2 and J5 will be continued since the data to date indicates that this approach compares favorably to that obtained in the allogeneic matched system. Studies with the B1 protocol indicate it to be a major new therapeutic modality in previously unresponsive non-Hodgkins's lymphomas. Anti-B-lym peptide antibodies will be utilized for the isolation and characterization of B-lym antigens and it is hoped that these new classes of reagents will complement existing antibodies for the characterization of leukemias. Drs. Kufe, Faller and Frei have demonstrated new pharmacologic approaches which can optimize the treatment of AML, ALL and other tumors. These investigations will continue to exploit combination chemotherapy for the cytoirradication of residual tumor in autologous transplants, asparaginase treatment for ALL and low dose ara-C. Progress made by Drs. Sallan, Weinstein and Mayer in the treatment of ALL and AML utilizing chemotherapy and immunotherapy lend hope to the view that the majority of these diseases will be ultimately curable. The present program has led to multiple interactions of individuals with interests in immunology, molecular biology, cell surface antigens, pharmacology, hematology and oncology. We believe that this integrated approach to cancer treatment and diagnosis has already resulted in a greater understanding of the malignant cell and its control.